^
Association details:
| Biomarker: | Low PLR |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Platelet-to-lymphocyte ratio in patients with metastatic breast cancer treated with eribulin.
Published date:
12/02/2023
Excerpt:
This retrospective study included 156 patients with recurrent/stage IV BC who received eribulin monotherapy...Multivariate analysis revealed low albumin-bilirubin grade (P< 0.001), high hemoglobin (P< 0.01), and low PLR (P< 0.05) as independent factors of longer OS after eribulin administration. Low PLR, anemia, and liver dysfunction might be factors associated with prolonged OS in patients with recurrent/stage IV BC on eribulin therapy...
